- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01433588
The Calmer Project
Calmer: A Novel Approach for Treating Infant Pain
The purpose of this study is to see if the Calmer is more effective at managing acute pain in preterm infants in the neonatal intensive care than the current standard of care in the unit.
Hypothesis: While receiving treatment with Calmer, infants will show lower behavioral pain scores and lower heart rates, and more stable autonomic regulation as measured by heart rate variability indices, than infants given a soother plus facilitated tucking (standard of care) during routine blood collection.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H3V4
- BC Children's and Women's Health Centre
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Stable infants admitted to the Neonatal Intensive Care Unit at Children's and Women's Health Centre of British Columbia (C&W)
- Preterm infants born at 27 to 36+6 completed weeks gestational age (GA) will be included
- GA is determined on the basis of the first day of the last menstrual period, early gestation ultrasonogram (in most cases) or best estimate based on neonatal examination
- Mothers must speak enough English to provide consent
Exclusion Criteria:
- Infants who have congenital anomalies, active, ongoing infection, or have undergone surgery
- Infants who have received pharmacological analgesics or sedatives within 72 hours of the assessment
- History of maternal abuse of controlled drugs and substances; blood collection that occurs beyond the 35th completed week (35 weeks + 6 days) GA
- Small for GA defined as a birth weight at least 2 standard deviations below mean for GA
- Higher order multiples (e.g. triplets)
- Infants in a cot
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Actieve vergelijker: Calmer
This therapeutic platform, called the Calmer interacts with the infant to help reduce stress to help promote better outcomes.
It is being tested to see if it mimics Kangaroo care, maternal skin to skin, to help promote better health outcomes.
Infants would be placed on it prior, during and after bloodwork to see if it elicits a favorable response.
|
This platform, called the Calmer, interacts with the infant to help reduce stress to help promote better outcomes.
Infants can be placed on it for care to mimic Kangaroo Care, maternal skin to skin.
|
Placebo-vergelijker: Standard Care
Standard of care during bloodwork is receiving a soother and facilitated tucking.
|
Infant would receive the standard of care for bloodwork, provided a soother and facilitated tucking.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Change in Behavioral Indicators of Infant Pain (BIIP) Score
Tijdsspanne: During the assessment period in the study, estimated to occur around one hour.
|
The Behavioral Indicators of Infant Pain (BIIP) is a reliable and valid scale for assessing acute procedural pain in preterm infants.
|
During the assessment period in the study, estimated to occur around one hour.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Secondary Outcome Measures: Heart Rate
Tijdsspanne: During and after the assessment period in the study, estimated to be 6 hours.
|
Heart rate will be recorded during the assessment period, one hour, to denote changes.
Additionally, the heart rate will be recorded after the assessment period, for approximately 5 hours.
|
During and after the assessment period in the study, estimated to be 6 hours.
|
Secondary Outcome Measures: Heart Rate Variability
Tijdsspanne: During and after assessment period in the study, estimated to be 6 hours.
|
Heart rate variability during the assessment period will be recorded, monitored and reviewed for changes, estimated to occur over the course of an hour.
Additionally, the heart rate variability will be recorded after the assessment period, for approximately 5 hours.
|
During and after assessment period in the study, estimated to be 6 hours.
|
Secondary Outcome Measures: NIRS
Tijdsspanne: During the assessment period in the study, estimated to occur over less than an hour.
|
Brain blood oxy- and de-oxyhemoglobin, TSI, total hemoglobin, using near infra-red spectroscopy.
During the assessment period in the study, estimated to occur around one hour.
|
During the assessment period in the study, estimated to occur over less than an hour.
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Liisa Holsti, PhD, Developmental Neurosciences and Child Health, Child and Family Research Institute and Dept. of Occupational Science and Occupational Therapy, UBC
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CALMERP
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op The Calmer
-
Memorial Sloan Kettering Cancer CenterBeëindigdDe familie of verwanten van patiënten die bij MSKCC zijn behandeld voor niet-cutane plaveiselcelcarcinomen van de | Bovenste spijsverteringskanaalVerenigde Staten
-
University of VictoriaVoltooid
-
University of New BrunswickHorizon Health Network; Universite de Moncton; New Brunswick Health Research Foundation en andere medewerkersVoltooid
-
Yu-Hsiang WuNational Institute on Deafness and Other Communication Disorders (NIDCD)Werving
-
Duke UniversityVoltooidSeksuele voorlichtingVerenigde Staten
-
Asian Institute of Gastroenterology, IndiaOvesco Endoscopy AGNog niet aan het werven
-
VA Office of Research and DevelopmentVoltooidNormaal gehoor | Tinnitus | GehoorapparatenVerenigde Staten
-
University of PittsburghNational Institute on Aging (NIA)WervingMobiliteitsbeperkingVerenigde Staten
-
LeMaitre VascularAvaniaWervingTrombus | Embolus | Occlusie; SchipDuitsland, Zwitserland